Emerging Medical Treatments for Meningioma in the Molecular Era

Fares Nigim; Hiroaki Wakimoto; Ekkehard M. Kasper; Linda Ackermans; Yasin Temel

doi:10.3390/biomedicines6030086

Emerging Medical Treatments for Meningioma in the Molecular Era

Fares Nigim, Hiroaki Wakimoto, Ekkehard M. Kasper, Linda Ackermans, Yasin Temel

Research output: Contribution to journal › Review article › Academic › peer-review

Original language	English
Article number	86
Number of pages	21
Journal	Biomedicines
Volume	6
Issue number	3
DOIs	https://doi.org/10.3390/biomedicines6030086
Publication status	Published - 1 Sep 2018

Keywords

World Health Organization (WHO)
Grade I
II
and III Meningiomas
High Grade Meningiomas (HGMs)
tumor heterogeneity
genetic subtypes
overall survival (OS)
progression free survival (PFS)
targeted therapy
clinical trials
oncolytic virus (OV)
TERT PROMOTER MUTATIONS
GROWTH-FACTOR RECEPTOR
FOCAL-ADHESION KINASE
TUMOR-SUPPRESSOR GENE
HERPES-SIMPLEX-VIRUS
SKULL BASE MENINGIOMAS
OF-THE-LITERATURE
PHASE-II TRIAL
INTEGRATIVE GENOMIC ANALYSIS
PLECKSTRIN HOMOLOGY DOMAIN
RECURRENT MENINGIOMAS
SONIC HEDGEHOG PATHWAY

Access to Document

10.3390/biomedicines6030086

Cite this

Nigim, F., Wakimoto, H., Kasper, E. M., Ackermans, L., & Temel, Y. (2018). Emerging Medical Treatments for Meningioma in the Molecular Era. Biomedicines, 6(3), [86]. https://doi.org/10.3390/biomedicines6030086

@article{63fb8d7b170a4e70845fcaa432bb50e2,

title = "Emerging Medical Treatments for Meningioma in the Molecular Era",

keywords = "World Health Organization (WHO), Grade I, II, and III Meningiomas, High Grade Meningiomas (HGMs), tumor heterogeneity, genetic subtypes, overall survival (OS), progression free survival (PFS), targeted therapy, clinical trials, oncolytic virus (OV), TERT PROMOTER MUTATIONS, GROWTH-FACTOR RECEPTOR, FOCAL-ADHESION KINASE, TUMOR-SUPPRESSOR GENE, HERPES-SIMPLEX-VIRUS, SKULL BASE MENINGIOMAS, OF-THE-LITERATURE, PHASE-II TRIAL, INTEGRATIVE GENOMIC ANALYSIS, PLECKSTRIN HOMOLOGY DOMAIN, RECURRENT MENINGIOMAS, SONIC HEDGEHOG PATHWAY",

author = "Fares Nigim and Hiroaki Wakimoto and Kasper, {Ekkehard M.} and Linda Ackermans and Yasin Temel",

year = "2018",

month = sep,

day = "1",

doi = "10.3390/biomedicines6030086",

language = "English",

volume = "6",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "3",

}

TY - JOUR

T1 - Emerging Medical Treatments for Meningioma in the Molecular Era

AU - Nigim, Fares

AU - Wakimoto, Hiroaki

AU - Kasper, Ekkehard M.

AU - Ackermans, Linda

AU - Temel, Yasin

PY - 2018/9/1

Y1 - 2018/9/1

KW - World Health Organization (WHO)

KW - Grade I

KW - II

KW - and III Meningiomas

KW - High Grade Meningiomas (HGMs)

KW - tumor heterogeneity

KW - genetic subtypes

KW - overall survival (OS)

KW - progression free survival (PFS)

KW - targeted therapy

KW - clinical trials

KW - oncolytic virus (OV)

KW - TERT PROMOTER MUTATIONS

KW - GROWTH-FACTOR RECEPTOR

KW - FOCAL-ADHESION KINASE

KW - TUMOR-SUPPRESSOR GENE

KW - HERPES-SIMPLEX-VIRUS

KW - SKULL BASE MENINGIOMAS

KW - OF-THE-LITERATURE

KW - PHASE-II TRIAL

KW - INTEGRATIVE GENOMIC ANALYSIS

KW - PLECKSTRIN HOMOLOGY DOMAIN

KW - RECURRENT MENINGIOMAS

KW - SONIC HEDGEHOG PATHWAY

U2 - 10.3390/biomedicines6030086

DO - 10.3390/biomedicines6030086

M3 - Review article

VL - 6

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 3

M1 - 86

ER -